Venlafaxine XR more dangerous than SSRIs in overdoseOverdose with venlafaxine may be associated with a higher risk of fatal outcome compared to overdose with selective serotonin reuptake inhibitor antidepressants, but lower than that seen with tricyclic antidepressants. CMA to launch fact-finding mission on European health-care reformDr. Robert Ouellet, president of the CMA, today announced the CMA's intention to begin an international fact-finding mission examining ideas for health care reform and renewal in several European countries. Voltaren Emulgel: nonprescription topical NSAID Novartis Consumer Healthcare is introducing the first nonprescription topical nonsteroidal anti-inflammatory drug to be marketed in Canada. Head lice: updated statement The Canadian Paediatric Society has issued a revised statement on the diagnosis and management of head lice. Revlimid approved for multiple myeloma Celgene's Revlimid (lenalidomide 15 mg and 25 mg capsules) is now indicated for the treatment of multiple myeloma (in combination with dexamethasone) in patients who have received at least one prior therapy. Ont. survey shows painkiller addiction growing concern Team-based approach to treatment could help. Spotlight: Lighting a spark in the profession Susan Beresford juggles involvement in six professional bodies, in addition to her full-time job as dispensary manager. Practice Issues: Adverse reactions - ACEI- and ARB-induced angioedema Angioedema is a self-limiting, nonpitting edema that occurs in the skin and mucous membranes. A Question of Ethics Can pharmacy accommodate differing principles? Managing statin-induced myalgia Muscle symptoms are the most prevalent and important adverse effects associated with stain therapy, and often result in suboptimal adherence. First Previous 1741 1742 1743 1744 1745 Next Last
